Bora CDMO Bora CDMO

X

Find Drugs in Development News & Deals for Beta Glucan

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
44
INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

SERVICES

0

  • Deals

Details:

The agreement grants Define Biotech the exclusive right to distribute maitake mushroom, rich in bioactive polysaccharides, especially beta-glucans, as new dietary supplement in China and Taiwan in exchange for the commitment of the new product over the three-year period.


Lead Product(s): Beta Glucan

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Small molecule

Partner/Sponsor/Collaborator: ABVC BioPharma

Deal Size: $3.0 million Upfront Cash: Undisclosed

Deal Type: Agreement December 09, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The effect of oat beta glucan on the study primary endpoint is change in LDL-C, and some positive findings observed with different parameters, there were dosage-related responses in weight and body-mass index at 12 weeks but they also did not reach statistical significance.


Lead Product(s): Beta Glucan

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 17, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the collaboration, pre-clinical studies using methods developed by the Angiogenesis Foundation will be conducted to characterize the in vivo bioactivity of Ceapro’s oat-derived bioactive products, beta glucan and avenanthramides.


Lead Product(s): Beta Glucan

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: Angiogenesis Foundation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration August 23, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY